• Publications
  • Influence
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
TLDR
The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel. Expand
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
TLDR
In patients with acute coronary syndrome receiving aspirin, a strategy of clopidogrel pretreatment followed by long-term therapy is beneficial in reducing major cardiovascular events, compared with placebo. Expand
Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials.
TLDR
This meta-analysis found that radial access reduced major bleeding and there was a corresponding trend for reduction in ischemic events compared to femoral access, and large randomized trials are needed to confirm the benefit of radial access on death and isChemic events. Expand
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial
TLDR
The lower rate of local vascular complications may be a reason to use the radial approach in patients with acute coronary syndromes who were undergoing coronary angiography with possible intervention. Expand
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes
TLDR
In ACS patients without persistent ST-segment elevation, there is a strong, consistent, temporal, and dose-related association between bleeding and death, and a similar association was evident between major bleeding and ischemic events, including myocardial infarction and stroke. Expand
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
TLDR
Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity. Expand
Early versus delayed invasive intervention in acute coronary syndromes.
TLDR
Early intervention did not differ greatly from delayed intervention in preventing the primary outcome, but it did reduce the rate of the composite secondary outcome of death, myocardial infarction, or refractory ischemia and was superior to delayed Intervention in high-risk patients. Expand
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
TLDR
In patients with STEMI, particularly those not undergoing primary percutaneous coronary intervention, fondaparinux significantly reduces mortality and reinfarction without increasing bleeding and strokes. Expand
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
TLDR
In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher- dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke. Expand
...
1
2
3
4
5
...